Orlando, FLORIDA14 Active Studies

Lung Cancer Clinical Trials in Orlando, FLORIDA

Find 14 actively recruiting lung cancer clinical trials in Orlando, FLORIDA. Connect with local research sites and explore new treatment options.

14
Active Trials
11
Sponsors
6,625
Enrolling

Recruiting Lung Cancer Studies in Orlando

RecruitingOrlando, FLORIDANCT05984277

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy...

1,200 participants
AstraZeneca
View Study Details
RecruitingOrlando, FLORIDANCT06077760

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (...

868 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingOrlando, FLORIDANCT05211895

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with du...

860 participants
AstraZeneca
View Study Details
RecruitingOrlando, FLORIDANCT06635824

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in ...

702 participants
Genmab
View Study Details
RecruitingOrlando, FLORIDANCT05671510

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who h...

600 participants
OncoC4, Inc.
View Study Details
RecruitingOrlando, FLORIDANCT06203210

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC)....

540 participants
Daiichi Sankyo
View Study Details
RecruitingOrlando, FLORIDANCT05498428

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneou...

390 participants
Janssen Research & Development, LLC
View Study Details
RecruitingOrlando, FLORIDANCT05261399

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and...

324 participants
AstraZeneca
View Study Details
RecruitingOrlando, FLORIDANCT06452277

A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutat...

278 participants
Bayer
View Study Details
RecruitingOrlando, FLORIDANCT06745323

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

The primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC)....

240 participants
Amgen
View Study Details
RecruitingOrlando, FLORIDANCT05142696

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

This study aims to establish a safe and well tolerated dose of \[177Lu\]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of t...

200 participants
Novartis Pharmaceuticals
View Study Details
RecruitingOrlando, FLORIDANCT04614103

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer...

170 participants
Iovance Biotherapeutics, Inc.
View Study Details
RecruitingOrlando, FLORIDANCT06667908

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can i...

130 participants
Johnson & Johnson Enterprise Innovation Inc.
View Study Details
RecruitingOrlando, FLORIDANCT06362252

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participan...

123 participants
Daiichi Sankyo
View Study Details

About Lung Cancer Clinical Trials in Orlando

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 14 lung cancer clinical trials recruiting participants in Orlando, FLORIDA. These studies are seeking a combined 6,625 participants. Research is being sponsored by AstraZeneca, Merck Sharp & Dohme LLC, Genmab and 8 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Orlando — FAQ

Are there lung cancer clinical trials in Orlando?

Yes, there are 14 lung cancer clinical trials currently recruiting in Orlando, FLORIDA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Orlando?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Orlando research site will contact you about next steps.

Are clinical trials in Orlando free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Orlando studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 14 active trials in Orlando are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated March 2, 2026 from ClinicalTrials.gov